Identifying a transcriptional core regulatory circuitry and other critical transcription factor dependencies in H3.3 G34R/V high-grade glioma
鉴定 H3.3 G34R/V 高级神经胶质瘤中的转录核心调节电路和其他关键转录因子依赖性
基本信息
- 批准号:10610342
- 负责人:
- 金额:$ 4.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAddressAdolescent and Young AdultAgeAnatomyApoptoticBiological AssayBiologyBrainBrain NeoplasmsCRISPR correctionCRISPR/Cas technologyCancer EtiologyCell LineCell ProliferationCell SurvivalCellsCentral Nervous SystemCerebral cortexChIP-seqChemotherapy and/or radiationChildChildhoodChildhood Brain NeoplasmChildhood GliomaChromatinClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCollectionComplexDNA BindingDNA Binding DomainDNA MethylationDataDependenceDevelopmentDevelopmental GeneDiseaseEnhancersEpigenetic ProcessEssential GenesEtiologyExcisionExclusionExhibitsFrequenciesGene ExpressionGene Expression ProfileGenesGenetic TranscriptionGenomicsGliomaHistone H3Histone H3.3In Situ Nick-End LabelingIndividualInterneuronsInvestigationLabelLaboratoriesMalignant Childhood NeoplasmMalignant NeoplasmsMapsMediatingMentorsModelingMolecularMolecular ProfilingMorbidity - disease rateMutateMutationNeuronsOncogenicOperative Surgical ProceduresPatientsPatternPhysiologicalPrimary NeoplasmQuantitative Reverse Transcriptase PCRRNA InterferenceRadiation therapyRecurrenceRegulator GenesResearchRoleSmall Interfering RNASpecific qualifier valueTechniquesTherapeuticTumor Stem CellsWestern BlottingXenograft procedurecancer cellclinical trainingcurative treatmentsexperiencegenome-widegenomic platformglioma cell linehuman stem cellsimprovedknock-downloss of functionmembermortalitymutantneoplastic cellneuro-oncologyneurosurgerynovelnovel therapeutic interventionnovel therapeuticsprogramsspatiotemporalstandard of carestem cell modelstem cellstranscription factortranscriptome sequencingtumortumorigenesis
项目摘要
Project Summary
Pediatric high-grade gliomas (HGGs) are devastating central nervous system malignancies. Despite decades of
investigation into these lethal childhood brain tumors, aggressive surgical resection combined with conventional
chemotherapy and radiation therapy remains the standard of care. Unfortunately, this treatment approach has
failed to improve the 5-year survival of patients with cortical HGGs, which continues to be less than 20%. The
paucity of curative treatment options for patients with HGGs emphasizes our urgent need to further understand
these disease entities at the cellular and molecular level for informed therapeutic approaches. The identification
of recurrent histone H3 mutations in pediatric HGGs by my mentor Dr. Suzanne J. Baker and others strongly
supports a critical role for epigenetic dysregulation in the etiology of childhood HGGs. Recurrent Gly34Arg/Val
substitutions in histone H3.3 (H3.3 G34R/V) occur in more than 15% of cerebral cortex HGGs found in
adolescents and young adults. The frequency of these mutations in a subset of cortical HGGs underscores the
functional significance of epigenetically dysregulated spatiotemporal gene regulatory programs during
development. However, the impact of H3.3 G34R/V on transcriptional regulatory programs contributing to
tumorigenesis in a distinct spatiotemporal context within the developing brain remains to be determined. This
proposal integrates the expertise of the Baker lab for functional and mechanistic studies in HGG with the
pioneering expertise of a group of collaborators who have identified and functionally validated transcriptional
core regulatory circuitries (CRC) and other critical tumor dependencies in models of pediatric cancer. By
combining cutting-edge genomic platforms and other experimental techniques with clinical training experiences
in pediatric neuro-oncology and neurosurgery, I intend to decipher complex transcriptional patterns dysregulated
in H3.3 G34R/V HGG to address current limitations in treating this intractable central nervous system
malignancy. The Baker lab established a novel collection of age and anatomically matched primary tumors,
patient-derived orthotopic xenografts, and a range of cell lines modeling wild-type, mutant, and CRISPR-
corrected H3.3 backgrounds for experimental interrogation of transcriptional dysregulation in HGG. Aim 1
leverages chromatin-based assays and RNA interference to identify transcription factors (TF) comprising a
transcriptional CRC essential to maintaining an oncogenic cellular state in H3.3 G34R/V HGG. Aim 2 employs
CRISPR/Cas9 negative selection screens to comprehensively target TF DNA-binding domains in patient-derived
cell lines from H3.3 G34R HGG and expands beyond core TFs comprising a transcriptional CRC to uncover
other critical TF gene dependencies in H3.3 G34R HGG. The identification of critical TF gene dependencies in
H3.3 G34R/V HGG will enhance our understanding of cancer cell dependency on transcriptional regulatory
programs and illuminate potentially actionable biology for the development of novel therapeutic strategies.
项目摘要
儿童高级别胶质瘤(HGG)是一种毁灭性的中枢神经系统恶性肿瘤。尽管经过数十年的
研究这些致命的儿童脑肿瘤,积极的手术切除结合传统的
化疗和放疗仍然是标准治疗。不幸的是,这种治疗方法
未能改善皮质HGG患者的5年生存率,其持续低于20%。的
HGG患者的治愈性治疗选择的缺乏强调了我们迫切需要进一步了解
这些疾病实体在细胞和分子水平的知情治疗方法。识别
我的导师Suzanne J. Baker博士和其他人强烈认为,
支持表观遗传失调在儿童HGG病因学中的关键作用。复发性Gly 34 Arg/瓦尔
组蛋白H3.3(H3.3 G34 R/V)的取代发生在大脑皮质HGG中的15%以上,
青少年和年轻人。这些突变在皮质HGG亚群中的频率强调了
表观遗传学失调的时空基因调控程序的功能意义
发展然而,H3.3 G34 R/V对转录调控程序的影响有助于
在发育中的脑内的不同时空背景下的肿瘤发生仍有待确定。这
该提案将Baker实验室在HGG功能和机制研究方面的专业知识与
一组合作者的开创性专业知识,他们已经确定并功能验证了转录
核心调节电路(CRC)和其他关键的肿瘤依赖性在儿科癌症模型。通过
将尖端的基因组平台和其他实验技术与临床培训经验相结合
在儿科神经肿瘤学和神经外科学中,我打算破译复杂的转录模式失调,
在H3.3 G34 R/V HGG中,以解决目前治疗这种难治性中枢神经系统的局限性
恶性肿瘤贝克实验室建立了一个新的年龄和解剖学匹配的原发性肿瘤集合,
患者来源的原位异种移植物,以及一系列模拟野生型、突变型和CRISPR的细胞系。
校正H3.3背景,用于HGG中转录失调的实验询问。要求1
利用基于染色质的测定和RNA干扰来鉴定转录因子(TF),
在H3.3 G34 R/V HGG中,转录CRC对于维持致癌细胞状态是必需的。Aim 2采用
CRISPR/Cas9阴性选择筛选以全面靶向患者来源的TF DNA结合结构域
H3.3 G34 R HGG的细胞系,并扩展到包含转录CRC的核心TF之外,以揭示
H3.3 G34 R HGG中的其他关键TF基因依赖性。关键TF基因依赖性的鉴定
H3.3 G34 R/V HGG将增强我们对癌细胞依赖于转录调控的理解
程序和照亮潜在的可操作的生物学为新的治疗策略的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jordan Trent Roach其他文献
Jordan Trent Roach的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jordan Trent Roach', 18)}}的其他基金
Identifying a transcriptional core regulatory circuitry and other critical transcription factor dependencies in H3.3 G34R/V high-grade glioma
鉴定 H3.3 G34R/V 高级神经胶质瘤中的转录核心调节电路和其他关键转录因子依赖性
- 批准号:
10462271 - 财政年份:2022
- 资助金额:
$ 4.37万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Research Grant